title: [Prevention of Pneumocystis carinii pneumonia with intermittent trimethoprim-sulfamethoxazole].
abstract: To evaluate efficacy and toxicity of intermittent trimethoprim-sulfamethoxazole (T/S) prophylaxis for Pneumocystis carinii pneumonia (PCP) our HIV-positive patients were given T/S (160 mg, 800 mg) twice daily for 3 consecutive days per week. Patients were included only if they met the CDC criteria for PCP prophylaxis, did not have intolerance to T/S, and if follow-up was 3 or more months. Thirty-eight patients received primary prophylaxis (Group I) for a mean period of 18.1 months and 26 patients received secondary prophylaxis (Group II) for a mean period of 15.5 months. Seventeen patients had adverse reactions (14 minor and 3 major reactions). PCP occurred in 1 patient in Group I after 20 months of T/S, and in 2 patients in Group II after 11 and 18 months of T/S. This pilot study suggests that intermittent T/S treatment is efficacious and relatively safe in the prophylaxis for PCP in HIV-positive patients.
authors.affiliation: Istituto di Malattie Infettive, Ospedale Civile, Università degli Studi di Verona.
authors.forename: R
authors.initials: R
authors.lastname: Luzzati
authors.forename: M C
authors.initials: MC
authors.lastname: Raviglione
mesh_terms: D015526:AIDS Dementia Complex / Q000150:complications; D000386:AIDS-Related Complex / Q000150:complications; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D012307:Risk Factors; D013997:Time Factors; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
chemical_list: D015662:Trimethoprim, Sulfamethoxazole Drug Combination
vernacular_title: Profilassi della polmonite da Pneumocystis carinii con trimetoprim-sulfametossazolo intermittente.